A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
The purpose of this study is to find out if an investigational drug called PV-10 given in combination with another drug called pembrolizumab can help people with metastatic melanoma.
Stage IV or unresectable stage III melanoma
At least 1 injectable lesion
Male and Female participants of 18 years of age and older.
Unresectable Stage III or Stage IV melanoma.
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will remain on the study until onset of disease progression, unmanageable toxicity or study termination by the Sponsor. You will be eligible to receive pembrolizumab for a maximum of 24 months while participating in this study. Afterwards, you will be contacted by the investigator or study team approximately every 12 weeks or more often to check on your health until end of the study. The estimated study duration is approximately 60 months.
Knight Clinical Trials Information Line
Provectus Biopharmaceuticals, Inc.